A plain-English look at Medpace's revenue, profit, and market value as the Cincinnati clinical-trial company grows into a $13 billion public firm.
A Lab Coat Company Behind the Scenes
Most people will never hear the name Medpace Holdings, Inc., yet its work touches the medicines that eventually reach pharmacy shelves. The Cincinnati, Ohio-based company doesn't make drugs itself. Instead, it runs the clinical trials, laboratory testing, and imaging work that smaller biotech and pharmaceutical firms need to get a new treatment through the approval process.
What the Company Actually Does
Medpace describes itself as a late-stage contract research organization, meaning it handles the detailed, regulated work of testing drugs and medical devices on behalf of clients who don't have the infrastructure to do it themselves. Its services stretch from bioanalytical lab work to imaging capabilities, supporting small and midsize firms that are racing to bring new therapies to market. Founded more than 30 years ago, the company now employs approximately 6,300 people, with operations centered in the United States and a presence spanning Europe, Asia, South America, Africa, and Australia.
Sizing Up the Revenue
In its most recent fiscal year, Medpace generated $2.5 billion in revenue. That's a meaningful sum for a services company, and it reflects steady demand from the biotech and pharmaceutical sector for outsourced trial management. Revenue has grown 121% from fiscal year 2021 to fiscal year 2025, a pace that signals the company has been winning more client work rather than simply riding industry-wide growth.
Profitability in Plain Terms
Medpace turned a net income of $451.1 million in FY2025, meaning the company is solidly profitable rather than burning cash to chase growth. Its gross margin sits at 30.1%, and its net margin comes in at 17.8%. In simple terms, for every dollar of revenue that comes in, roughly 18 cents ends up as bottom-line profit after all expenses are paid — a healthy figure for a services-based business.
What the Balance Sheet Shows
The company reports total assets of $2.0 billion. That figure gives a sense of the physical and financial resources — labs, equipment, cash, and other holdings — that support its day-to-day operations across dozens of countries.
Market Value and Trading Activity
Medpace trades publicly on the NASDAQ under the ticker MEDP. Its market capitalization stands at $13.0 billion, and shares recently changed hands at $605.82, with the stock trading near its 52-week high. The company is valued at a price-to-earnings ratio of 39.6, a figure that reflects how much investors are currently paying for each dollar of the company's earnings.
A Look Back at the IPO
Medpace went public in August 2016, and the company has been trading on the open market ever since. The move from a privately run research firm to a publicly traded company gave outside investors a way to participate in its growth within the pharmaceutical services space.
Where It Fits in the Industry
Medpace operates squarely within the pharmaceuticals industry, but its role is a supporting one — it's the infrastructure behind drug development rather than a drugmaker itself. As biotech and pharmaceutical companies continue to rely on outside partners for clinical trial work, Medpace's scale and international reach position it as a significant player in that supply chain.
The Bottom Line
This snapshot draws on Medpace's publicly reported financial figures and market data as of the most recent available reporting, and it is intended as factual information only — not investment advice.
